BiVax: A peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses

Hyun Il Cho, Kelly Barrios, Young Ran Lee, Angelika K. Linowski, Esteban Celis

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Therapeutic vaccines for the treatment of cancer are an attractive alternative to some of the conventional therapies that are currently used. More importantly, vaccines could be very useful to prevent recurrences when applied after primary therapy. Unfortunately, most therapeutic vaccines for cancer have performed poorly due to the low level of immune responses that they induce. Previous work done in our laboratory in cancer mouse models demonstrated that vaccines consisting of synthetic peptides representing minimal CD8 T-cell epitopes administered i.v. mixed with poly-IC and anti-CD40 antibodies (TriVax) were capable of inducing massive T cell responses similar to those found during acute infections. We now report that some peptides are capable of inducing similarly large T cell responses after vaccination with poly-IC alone (BiVax). The results show that amphiphilic peptides are more likely to function as strong immunogens in BiVax and that systemic immunizations (i.v. or i.m.) were more effective than local (s.c.) vaccine administration. The immune responses induced by BiVax were found to be effective against established tumors in two mouse cancer models. The roles of various immune-related pathways such as type-I IFN, CD40 costimulation, CD4 T cells, TLRs and the MDA5 RNA helicase were examined. The present findings could facilitate the development of simple and effective subunit vaccines for diseases where CD8 T cells provide a therapeutic benefit.

Original languageEnglish (US)
Pages (from-to)787-799
Number of pages13
JournalCancer Immunology, Immunotherapy
Volume62
Issue number4
DOIs
StatePublished - Apr 1 2013

Fingerprint

Subunit Vaccines
T-Lymphocytes
Peptides
Infection
Neoplasms
Cancer Vaccines
Therapeutics
Vaccines
RNA Helicases
Synthetic Vaccines
T-Lymphocyte Epitopes
Anti-Idiotypic Antibodies
Immunization
Vaccination
Recurrence

Keywords

  • CD8 T cells
  • Immune adjuvants
  • Immunotherapy
  • Peptide vaccines
  • Type-I interferon

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

BiVax : A peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses. / Cho, Hyun Il; Barrios, Kelly; Lee, Young Ran; Linowski, Angelika K.; Celis, Esteban.

In: Cancer Immunology, Immunotherapy, Vol. 62, No. 4, 01.04.2013, p. 787-799.

Research output: Contribution to journalArticle

@article{c4a1ea05a8144ed4a34fcf56114ec090,
title = "BiVax: A peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses",
abstract = "Therapeutic vaccines for the treatment of cancer are an attractive alternative to some of the conventional therapies that are currently used. More importantly, vaccines could be very useful to prevent recurrences when applied after primary therapy. Unfortunately, most therapeutic vaccines for cancer have performed poorly due to the low level of immune responses that they induce. Previous work done in our laboratory in cancer mouse models demonstrated that vaccines consisting of synthetic peptides representing minimal CD8 T-cell epitopes administered i.v. mixed with poly-IC and anti-CD40 antibodies (TriVax) were capable of inducing massive T cell responses similar to those found during acute infections. We now report that some peptides are capable of inducing similarly large T cell responses after vaccination with poly-IC alone (BiVax). The results show that amphiphilic peptides are more likely to function as strong immunogens in BiVax and that systemic immunizations (i.v. or i.m.) were more effective than local (s.c.) vaccine administration. The immune responses induced by BiVax were found to be effective against established tumors in two mouse cancer models. The roles of various immune-related pathways such as type-I IFN, CD40 costimulation, CD4 T cells, TLRs and the MDA5 RNA helicase were examined. The present findings could facilitate the development of simple and effective subunit vaccines for diseases where CD8 T cells provide a therapeutic benefit.",
keywords = "CD8 T cells, Immune adjuvants, Immunotherapy, Peptide vaccines, Type-I interferon",
author = "Cho, {Hyun Il} and Kelly Barrios and Lee, {Young Ran} and Linowski, {Angelika K.} and Esteban Celis",
year = "2013",
month = "4",
day = "1",
doi = "10.1007/s00262-012-1382-6",
language = "English (US)",
volume = "62",
pages = "787--799",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "4",

}

TY - JOUR

T1 - BiVax

T2 - A peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses

AU - Cho, Hyun Il

AU - Barrios, Kelly

AU - Lee, Young Ran

AU - Linowski, Angelika K.

AU - Celis, Esteban

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Therapeutic vaccines for the treatment of cancer are an attractive alternative to some of the conventional therapies that are currently used. More importantly, vaccines could be very useful to prevent recurrences when applied after primary therapy. Unfortunately, most therapeutic vaccines for cancer have performed poorly due to the low level of immune responses that they induce. Previous work done in our laboratory in cancer mouse models demonstrated that vaccines consisting of synthetic peptides representing minimal CD8 T-cell epitopes administered i.v. mixed with poly-IC and anti-CD40 antibodies (TriVax) were capable of inducing massive T cell responses similar to those found during acute infections. We now report that some peptides are capable of inducing similarly large T cell responses after vaccination with poly-IC alone (BiVax). The results show that amphiphilic peptides are more likely to function as strong immunogens in BiVax and that systemic immunizations (i.v. or i.m.) were more effective than local (s.c.) vaccine administration. The immune responses induced by BiVax were found to be effective against established tumors in two mouse cancer models. The roles of various immune-related pathways such as type-I IFN, CD40 costimulation, CD4 T cells, TLRs and the MDA5 RNA helicase were examined. The present findings could facilitate the development of simple and effective subunit vaccines for diseases where CD8 T cells provide a therapeutic benefit.

AB - Therapeutic vaccines for the treatment of cancer are an attractive alternative to some of the conventional therapies that are currently used. More importantly, vaccines could be very useful to prevent recurrences when applied after primary therapy. Unfortunately, most therapeutic vaccines for cancer have performed poorly due to the low level of immune responses that they induce. Previous work done in our laboratory in cancer mouse models demonstrated that vaccines consisting of synthetic peptides representing minimal CD8 T-cell epitopes administered i.v. mixed with poly-IC and anti-CD40 antibodies (TriVax) were capable of inducing massive T cell responses similar to those found during acute infections. We now report that some peptides are capable of inducing similarly large T cell responses after vaccination with poly-IC alone (BiVax). The results show that amphiphilic peptides are more likely to function as strong immunogens in BiVax and that systemic immunizations (i.v. or i.m.) were more effective than local (s.c.) vaccine administration. The immune responses induced by BiVax were found to be effective against established tumors in two mouse cancer models. The roles of various immune-related pathways such as type-I IFN, CD40 costimulation, CD4 T cells, TLRs and the MDA5 RNA helicase were examined. The present findings could facilitate the development of simple and effective subunit vaccines for diseases where CD8 T cells provide a therapeutic benefit.

KW - CD8 T cells

KW - Immune adjuvants

KW - Immunotherapy

KW - Peptide vaccines

KW - Type-I interferon

UR - http://www.scopus.com/inward/record.url?scp=84877825063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877825063&partnerID=8YFLogxK

U2 - 10.1007/s00262-012-1382-6

DO - 10.1007/s00262-012-1382-6

M3 - Article

C2 - 23266830

AN - SCOPUS:84877825063

VL - 62

SP - 787

EP - 799

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 4

ER -